Overview

A Study to Evaluate the Safety and Effectiveness of Asoprisnil and Estrogen Administration to Postmenopausal Women

Status:
Completed
Trial end date:
2001-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine the safety and effectiveness of 3 asoprisnil doses when administered to postmenopausal women with Premarin® 0.625 mg.
Phase:
Phase 2
Details
Lead Sponsor:
Abbott
Treatments:
Estrogens
Estrogens, Conjugated (USP)